Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

ACTH (Cosyntropin/Cortrosyn) peptide icon, one bubble per amino acidACTH (Cosyntropin/Cortrosyn)24 residuesSYSMEHFRWGKPVGKKRRPVKVYPEach bubble = one amino acid. Size = residue mass. Color = chemical class.

ACTH (Cosyntropin/Cortrosyn)

ImmuneFDA Approved
15 min half-life·Injection

Also known as: ACTH, corticotropin, cosyntropin

Over 400 PubMed papers and six decades of clinical use make cosyntropin one of the most validated diagnostic tools in all of endocrinology. This synthetic 24-amino-acid fragment of ACTH triggers a measurable cortisol surge within 30 minutes, telling clinicians whether the adrenal glands can do their job. The full 39-amino-acid version, sold as HP Acthar Gel, carries FDA approval for infantile spasms, MS flares, and nephrotic syndrome. Cosyntropin isn't a research peptide or biohacking tool. It's a prescription diagnostic agent used in clinic settings, with a single standardized dose (250 mcg) that hasn't changed in decades.

What Is ACTH (Cosyntropin/Cortrosyn)?

Four hundred twenty-four PubMed-indexed papers, a 2023 patient-level meta-analysis (Kazlauskaite et al., PMC10045406), and decades of routine hospital use. That's the evidence base behind the cosyntropin stimulation test. Adrenocorticotropic hormone (ACTH, also known as corticotropin; CAS 9002-60-2) is a 39-amino-acid peptide produced by corticotroph cells in the anterior pituitary gland. Cosyntropin (brand name Cortrosyn) is the synthetic 24-amino-acid N-terminal fragment. It retains full biological activity at the melanocortin-2 receptor (MC2R) on adrenal cortical cells.

The test itself is simple. A clinician injects 250 mcg intravenously or intramuscularly, draws cortisol at baseline, 30 minutes, and 60 minutes. Peak cortisol at or above 18 mcg/dL means the adrenals are functioning. Anything below that threshold raises a red flag for Addison's disease or secondary adrenal insufficiency.

Beyond diagnostics, the full-length ACTH molecule appears in HP Acthar Gel, a repository corticotropin preparation derived from porcine pituitary extract. Acthar carries FDA approval for infantile spasms (first-line per AAP guidelines), MS exacerbations, nephrotic syndrome, and more than a dozen other inflammatory conditions. Its price tag, roughly $45,600 per vial, makes it one of the most expensive drugs in the United States.

Reddit mentions for cosyntropin sit near zero. There is no community peptide protocol. This is a clinical compound prescribed by endocrinologists, neurologists, and nephrologists. The plasma half-life is approximately 15 minutes, meaning it clears the body before the diagnostic blood draw at 60 minutes is even complete.

How ACTH (Cosyntropin/Cortrosyn) Works

ACTH binds to the melanocortin-2 receptor (MC2R), a G protein-coupled receptor found primarily on cells in the adrenal cortex zona fasciculata and zona reticularis. MC2R is unusual among melanocortin receptors because ACTH is its only known endogenous agonist. The receptor also requires a chaperone protein called MRAP1 (melanocortin-2 receptor accessory protein) to reach the cell surface. Without MRAP1, MC2R gets trapped in the endoplasmic reticulum and degraded.

Once ACTH locks onto MC2R, the receptor activates the stimulatory G-protein (Gs). Gs turns on adenylyl cyclase, which converts ATP into cyclic AMP. Rising cAMP levels activate protein kinase A (PKA). PKA then phosphorylates two key enzymes in the steroidogenic pathway: StAR protein and CYP11A1 (cytochrome P450 side-chain cleavage enzyme). Together, these drive the rate-limiting conversion of cholesterol into pregnenolone. The downstream result is cortisol, corticosterone, and adrenal androgen production.

ACTH-related melanocortin peptides also activate MC1R, MC3R, MC4R, and MC5R on immune cells (macrophages, lymphocytes, dendritic cells). This explains why Acthar Gel produces anti-inflammatory effects independent of cortisol. Those non-steroidogenic effects include suppression of NF-kB signaling and reduced pro-inflammatory cytokine release.

ACTH (Cosyntropin/Cortrosyn) Benefits

  • ACTH benefits center on its dual role as a diagnostic gold standard and a therapeutic option for severe inflammatory conditions.
  • Cosyntropin has been the international standard for diagnosing adrenal insufficiency for over 50 years, used in virtually every endocrinology practice worldwide.
  • Acthar Gel achieves approximately 87% response rates for infantile spasms in published series, earning first-line recommendation from the American Academy of Pediatrics and Child Neurology Society.
  • MS exacerbation treatment with Acthar Gel (80-120 U/day for 2-3 weeks) provides an alternative for patients who cannot tolerate IV methylprednisolone.
  • Direct immunomodulatory effects through melanocortin receptors on immune cells offer a mechanism distinct from simple cortisol elevation, suppressing NF-kB signaling and B-cell antibody production [1].
  • The 2023 meta-analysis by Kazlauskaite's group (PMC10045406) confirmed that even the low-dose 1 mcg protocol detects secondary adrenal insufficiency with higher sensitivity than the standard 250 mcg dose.

ACTH (Cosyntropin/Cortrosyn): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 5 key studies·FDA-approved

Cosyntropin is one of the most validated diagnostic tools in endocrinology, with over 400 PubMed-indexed papers spanning decades.

Dosing studied: 250 mcg single dose IV/IM (diagnostic). Acthar Gel: 40-150 U/m²/day depending on indication (therapeutic).
Read the evidence (key study, limitations)

The 250 mcg stimulation test is the international standard for evaluating adrenal reserve. A 2023 patient-level meta-analysis found the low-dose test (1 mcg) has better sensitivity for detecting secondary adrenal insufficiency than the standard 250 mcg dose, but the standard dose remains the clinical default due to simplicity and reproducibility. Acthar Gel therapeutic efficacy is well-documented for infantile spasms (first-line per AAP guidelines), MS exacerbations, and nephrotic syndrome, but its advantages over cheaper corticosteroid alternatives are debated.

Key Study

Kazlauskaite et al. 2023, "ACTH Stimulation Test for the Diagnosis of Secondary Adrenal Insufficiency: Light and Shadow" (PMC10045406): patient-level meta-analysis showing low-dose test superiority for secondary AI detection

Limitations

The standard 250 mcg dose provides supraphysiologic stimulation that may mask mild or early secondary adrenal insufficiency: a known limitation. The low-dose (1 mcg) protocol isn't FDA-approved and requires dilution of the 250 mcg vial, introducing preparation variability. Acthar Gel's superiority over IV methylprednisolone for MS is not established: the high price tag makes the cost-benefit analysis unfavorable for many indications.

Community Experience
Weak
3.5/5
Based on Drugs.com: 11 reviews (avg 4.7/10). Inspire forums: scattered nephrotic syndrome discussions. Reddit: effectively zero research peptide discussion. Mallinckrodt RISE survey (2024-2025): n=54 SelfJect users.

There is effectively no community use of cosyntropin as a research peptide.

Community dosing: N/A: not community-used. All dosing is physician-directed per FDA label.
Read the reports (what users report 3, common issues 5)

Reddit mentions are near zero. This is a clinical diagnostic agent administered by doctors in clinic settings: it has no application in the peptide optimization community. Acthar Gel patient communities exist (primarily for infantile spasms and MS), but discussion centers on cost, insurance battles, and side effects, not self-directed protocols.

What users report (3)
  • Acthar Gel for infantile spasms: parents describe it as life-changing when other treatments fail
  • MS exacerbation relief: some patients prefer it to IV steroids for relapse management
  • Acthar Gel SelfJect auto-injector makes home administration easier than older vial-and-syringe method
Common issues (5)
  • Cost is the overwhelming complaint: ~$45,600 per vial makes it one of the most expensive drugs in the US
  • Insurance denials and prior authorization battles are routine
  • Cushingoid side effects with chronic use: weight gain, moon face, fluid retention
  • Hyperglycemia requiring monitoring or treatment adjustment
  • Mood changes and insomnia during therapeutic courses
Science-Only Evidence

Scientific data is extensive for cosyntropin as a diagnostic tool and Acthar Gel as a therapeutic agent. There is no community peptide use to align with: this is a clinical-only compound. The "community" that exists (Acthar Gel patients) interacts with this drug exclusively through physician prescriptions, not self-directed protocols.

ACTH (Cosyntropin/Cortrosyn) Dosage Guide

FDA LabelCortrosyn (cosyntropin) FDA Prescribing Information (2023)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner250 mcgSingle dose
Moderate250 mcgSingle dose
Aggressive250 mcgSingle dose
Note:

Cosyntropin comes in a 0.25 mg vial. Reconstitute with 1 mL of normal saline (0.9% NaCl), not bacteriostatic water. The manufacturer is specific about this. You'll draw up the entire 1 mL for the full 250 mcg diagnostic dose. There's no partial dosing for adults.

The timing matters more than most people realize. Morning testing (8-9 AM) is preferred because cortisol follows a diurnal rhythm; afternoon testing can produce misleading baseline values. Draw your baseline cortisol before touching the cosyntropin. Then collect at both 30 and 60 minutes. Some patients with intact adrenal function peak late, and calling it a failure based on one timepoint is a common diagnostic error.

Stop glucocorticoids on the day of testing. Estrogen-containing drugs need a 4-6 week washout because they raise cortisol-binding globulin. Miss that detail and you'll get a falsely raised total cortisol reading.

Use reconstituted cosyntropin immediately. Don't store it. Don't batch it. One vial, one test, one patient.

Cycling

Neither form of ACTH is cycled. Cosyntropin (Cortrosyn) is one 0.25 mg injection in adults to screen for adrenocortical insufficiency, not a course (Cortrosyn label, sections 1, 2.2 and 16). Acthar Gel runs as a course or a per-patient schedule, never an on/off cycle. For infantile spasms, the Acthar Gel label gives 150 U/m2 a day over a 2-week period (section 2.2). Dosing is then "gradually tapered over a 2-week period to avoid adrenal insufficiency." Acute multiple sclerosis exacerbations get 80 to 120 units daily for 2-3 weeks (section 2.3). Stopping suddenly after prolonged use "may lead to adrenal insufficiency or recurrent symptoms" (sections 2.3 and 2.4). It may be necessary to taper the dose and lengthen the injection interval (sections 2.3, 2.4 and 5.2).

Calculate your ACTH (Cosyntropin/Cortrosyn) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

ACTH (Cosyntropin/Cortrosyn) Protocols by Goal

beginnerFDA LabelSingle visit (~1 hour)
Standard cosyntropin stimulation test
Wk Single visit
250 mcg (0.25 mg) · Single dose · IV push over 2 min or IM

Expected: Definitive assessment of adrenal reserve. Normal response: cortisol rises to ≥18-20 mcg/dL. Subnormal response indicates adrenocortical insufficiency requiring further workup (ACTH level to distinguish primary vs secondary AI).

Monitor: Cortisol assay at baseline, 30 min, 60 min. Some guidelines recommend measuring both timepoints: patients failing at 30 min may pass at 60 min.

How to Inject ACTH (Cosyntropin/Cortrosyn)

  1. 1
    Step 1

    Remove the flip-off seal from the cosyntropin 0.25 mg vial.

  2. 2
    Step 2

    Using a sterile syringe, inject 1 mL of 0.9% sodium chloride (normal saline) into the vial. Swirl gently until dissolved. The solution should be clear and colorless.

  3. 3
    Step 3

    Draw baseline serum cortisol before proceeding.

  4. 4
    Draw up the full 1 mL (250 mcg) into the syringe

    For IV administration, push slowly over 2 minutes. For IM, inject into the deltoid or gluteal muscle using a 22-25 gauge needle.

  5. 5
    Step 5

    Start a timer at the moment of injection.

  6. 6
    Step 6

    Draw serum cortisol at 30 minutes post-injection and again at 60 minutes. Label tubes clearly with draw times.

  7. 7
    Step 7

    Normal result: peak cortisol at or above 18-20 mcg/dL at either timepoint.

  8. 8
    Step 8

    For Acthar Gel (therapeutic use): administer IM or subcutaneously. Infantile spasms protocol calls for 150 U/m2/day divided into two injections. MS exacerbation dosing runs 80-120 units once daily for 2-3 weeks. Rotate injection sites for repeated dosing.

  9. 9
    Step 9

    Storage: cosyntropin vials store at room temperature (15-30 degrees C). Protect from light. Acthar Gel requires cold chain storage per Mallinckrodt labeling.

ACTH (Cosyntropin/Cortrosyn) Stacking Protocols

Works With

Avoid

Glucocorticoids (prednisone, hydrocortisone, dexamethasone)

Falsely elevate cortisol during diagnostic testing. For therapeutic Acthar Gel, concurrent glucocorticoids create additive immunosuppression and Cushingoid risk.

Do not combine
Estrogen-containing drugs (oral contraceptives, HRT)

Increase cortisol-binding globulin, falsely elevating total cortisol measurements. Stop 4-6 weeks before cosyntropin testing.

Spironolactone

Can interfere with cortisol assay results during stimulation testing.

Live vaccines

Contraindicated during therapeutic Acthar Gel use due to immunosuppressive effects: risk of disseminated infection.

Do not combine
Amphotericin B

Enhanced risk of severe hypokalemia when combined with corticotropin therapy.

Do not combine

Estimated Cost

Brand Price
Cortrosyn (cosyntropin): ~$50-$200 per 0.25 mg vial (hospital/clinic supply pricing). HP Acthar Gel: ~$45,600 per 5 mL vial (80 U/mL); SelfJect auto-injector packs $18,200-$36,500. Mallinckrodt raised Acthar Gel price 3% in January 2025.
Generic / Research
Generic cosyntropin available from Amphastar and others at similar pricing. No generic Acthar Gel exists: it has no therapeutic equivalent due to its unique porcine-derived formulation and orphan/grandfathered FDA status. Purified Cortrophin Gel (ANI Pharmaceuticals, NDA 008975) is a separate repository corticotropin application, not a generic of Acthar Gel.
Compounded
N/A: cosyntropin and Acthar Gel are not compounded. These are manufactured pharmaceutical products available only through regulated supply channels.

Pricing updated 2026-04-09

ACTH (Cosyntropin/Cortrosyn) Side Effects

Acthar Gel's chronic side effect profile looks a lot like what happens when you flood the body with cortisol, because that's exactly what it does. Cushingoid features (moon face, central weight gain, abdominal striae) develop in most patients by week two of daily dosing. This isn't a rare side effect. It's an expected pharmacologic consequence of sustained ACTH stimulation.

Hyperglycemia is the second concern that warrants real attention. ACTH-driven cortisol elevation raises blood glucose enough to unmask diabetes in predisposed patients. Blood glucose monitoring during any Acthar Gel course longer than a few days isn't optional.

Hypokalemia represents a less obvious but potentially dangerous risk. Mineralocorticoid effects from adrenal stimulation cause potassium wasting. The risk compounds when patients are also taking amphotericin B or loop diuretics. Weekly serum potassium checks are standard during therapeutic courses.

For the single diagnostic dose of cosyntropin (250 mcg), adverse effects are far less dramatic. Hypersensitivity reactions occur infrequently. Anaphylaxis is rare but documented even on first exposure, which is why every cosyntropin stimulation test requires epinephrine on hand and IV access established before the injection.

Published side effects from the single diagnostic dose include bradycardia, tachycardia, transient hypertension, peripheral edema, and injection-site rash. These are uncommon and typically self-limited.

Chronic Acthar Gel use carries additional risks: fluid retention, increased infection susceptibility, osteoporosis with prolonged courses, cataracts, peptic ulceration, mood disturbances (ranging from insomnia to frank psychosis), and skin hyperpigmentation from melanocortin receptor activation. Neutralizing antibody formation has been reported with prolonged administration.

Abrupt discontinuation after courses longer than one week can precipitate adrenal crisis. This is not a theoretical risk. HPA axis suppression from exogenous ACTH is predictable and dose-dependent. Tapering protocols are mandatory. If morning cortisol falls below 10 mcg/dL after completing a course, hydrocortisone bridging may be necessary until the axis recovers.

Pregnancy is not on either repository corticotropin label's contraindication list. The Acthar Gel label says it may cause fetal harm (section 8.1), and the Cortrophin label cites fetal abnormalities in animals, so use it only if the benefit justifies the risk. Breastfeeding requires caution since ACTH-stimulated cortisol elevation may affect nursing infants.

Common Issues & Solutions

Cortisol didn't reach 18 mcg/dL at 30 minutes? Always check the 60-minute draw: some patients with intact adrenal function have a delayed peak. Over-diagnosing adrenal insufficiency from a single timepoint is a common pitfall.

Used bacteriostatic water instead of normal saline? The manufacturer specifies 0.9% NaCl only. BAC water may affect stability. Re-do the test with proper reconstitution.

Patient on glucocorticoids? Prednisone, hydrocortisone, and dexamethasone must be discontinued on the day of testing. Estrogens need 4-6 weeks washout. A "failed" test on these drugs is a false result, not adrenal insufficiency.

Anaphylactic reaction during test? It's rare but documented even on first exposure. Always have epinephrine, IV access, and resuscitation equipment ready. Don't perform this test without emergency preparedness.

Acthar Gel too expensive to access? At ~$45,600 per vial, this is one of the most controversial drug prices in the US. Mallinckrodt offers patient assistance programs (Acthar Patient Support). Discuss alternatives with your prescriber: IV methylprednisolone covers many of the same indications at a fraction of the cost.

Ask AI about this page

Ask AI for a second opinion on ACTH (Cosyntropin/Cortrosyn) dosing and side effects

Contraindications

  • Primary adrenocortical insufficiency (adrenals cannot respond to ACTH stimulation)
  • Intravenous administration of repository corticotropin: contraindicated on the Acthar Gel and Purified Cortrophin Gel labels
  • Infants under 2 years of age with suspected congenital infections (Acthar Gel label)
  • Live or live attenuated vaccines during immunosuppressive doses of repository corticotropin (Acthar Gel label)
  • Systemic fungal infections or active untreated infections
  • Ocular herpes simplex: contraindicated on both repository corticotropin labels
  • Recent surgery: contraindicated on both repository corticotropin labels
  • Scleroderma (manufacturer contraindication for corticotropin therapy)
  • Peptic ulcer, active or by history: contraindicated on both repository corticotropin labels
  • Osteoporosis: contraindicated on both repository corticotropin labels
  • Congestive heart failure or uncontrolled hypertension (for therapeutic corticotropin)
  • Adrenocortical hyperfunction: contraindicated on both repository corticotropin labels
  • Sensitivity to proteins of porcine origin: contraindicated on both repository corticotropin labels
  • Hypersensitivity to cosyntropin or any component of the formulation
  • Prior hypersensitivity to corticotropin or any inactive ingredient: contraindicated on the Acthar Gel and Purified Cortrophin Gel labels since October 2026; reactions have included anaphylaxis and angioedema
  • Pregnancy: not a label contraindication, but the Acthar Gel label says it may cause fetal harm (section 8.1); use only if potential benefit justifies risk
  • Breastfeeding: ACTH-stimulated cortisol elevation may affect nursing infants; use with caution

Drug Interactions

  • Glucocorticoids and spironolactone: Falsely elevate cortisol levels during diagnostic testing; discontinue on day of test
  • Estrogen-containing drugs: Increase cortisol binding globulin levels; stop 4-6 weeks before cosyntropin testing
  • Amphotericin B: Enhanced risk of severe hypokalemia when combined with corticotropin therapy
  • Quinolone antibiotics: Increased risk of tendon rupture when co-administered with corticotropin
  • Live vaccines: Contraindicated during therapeutic corticotropin use due to immunosuppressive effects
  • NSAIDs (ibuprofen, naproxen, aspirin): increased GI bleeding risk from combined corticotropin-induced mucosal vulnerability; per Acthar Gel prescribing information
  • Oral anticoagulants (warfarin): corticotropin-driven cortisol elevation may alter coagulation factor synthesis; monitor INR when initiating or discontinuing corticotropin; per Acthar Gel prescribing information
  • Insulin and oral hypoglycemic agents: ACTH-driven adrenal cortisol elevation causes hyperglycemia; patients with diabetes may require dose adjustments during corticotropin therapy; per clinical pharmacology

Product Quality

Recommended Monitoring

TestWhenTarget
Serum cortisol (baseline, 30 min, 60 min)During cosyntropin stimulation test≥18-20 mcg/dL peak
Blood glucoseDuring and after Acthar Gel therapeutic coursesFasting <126 mg/dL
Serum potassiumWeekly during Acthar Gel therapy3.5-5.0 mEq/L
Blood pressureEach visit during Acthar Gel therapy<140/90 mmHg
Morning cortisol (post-treatment)After completing an Acthar Gel course >1 week≥10 mcg/dL (AM draw)
Serum cortisol (baseline, 30 min, 60 min)

The entire point of the diagnostic test: determines adrenal reserve adequacy

Blood glucose

Chronic ACTH stimulation elevates cortisol, which raises blood glucose. Can unmask diabetes.

Serum potassium

Mineralocorticoid effects cause potassium wasting: hypokalemia risk increases with concurrent amphotericin B or diuretics

Blood pressure

Fluid retention and mineralocorticoid effects raise blood pressure

Morning cortisol (post-treatment)

Assesses HPA axis recovery after exogenous ACTH suppression. Low morning cortisol indicates ongoing adrenal suppression requiring continued physiologic replacement.

ACTH (Cosyntropin/Cortrosyn) Before and After

0-30 minutes

Diagnostic: Cortisol begins rising within minutes of cosyntropin injection. Initial adrenal response measurable by 30 minutes post-dose.

30-60 minutes

Diagnostic: Peak cortisol response typically reached at 30-60 minutes. Normal response is cortisol ≥18-20 mcg/dL confirming adequate adrenal reserve.

1-2 weeks

Therapeutic (Acthar Gel): Clinical improvement in infantile spasms and MS exacerbations typically observed within the first 1-2 weeks of daily dosing.

2-4 weeks

Therapeutic: Full treatment effect realized. Begin tapering protocols to prevent adrenal suppression and rebound symptoms.

What to Expect

0-30 minutes (Diagnostic): Cortisol starts climbing within minutes of the cosyntropin injection. By 30 minutes, the adrenal response is measurable. This first blood draw gives an early read on whether the glands are responding. Cosyntropin's 15-minute half-life means it's already clearing the bloodstream at this point.

30-60 minutes (Diagnostic): Peak cortisol typically lands in this window. Anything at or above 18-20 mcg/dL confirms the adrenals have adequate reserve. Patients report the test itself as straightforward and painless. By 60 minutes, the cosyntropin has cleared plasma entirely.

1-2 weeks (Acthar Gel Therapeutic): Clinical improvement typically appears within the first two weeks of daily dosing. Parents of infants with West syndrome report dramatic spasm reduction early in this window. MS patients have more variable onset; some feel relief within days while others need the full course. Expect fluid retention, mood changes, increased appetite, insomnia, and raised blood glucose during this phase.

2-4 weeks (Acthar Gel Therapeutic): Full treatment effect is realized. Mandatory taper begins to prevent adrenal crisis and rebound. Cushingoid features have appeared in most patients by now (moon face, weight gain). Parents and MS patients describe the taper phase as challenging since symptoms can fluctuate. Hyperglycemia, hypokalemia, infection risk, and mood swings are common during this period.

Detailed Timeline: Science vs Community

0-30 minutes
Science

Cortisol begins rising within minutes of cosyntropin injection. Measurable cortisol increase at 30 minutes. Target: ≥18 mcg/dL.

Community

N/A: not community-used. Patients report the test itself is straightforward and painless.

30-60 minutes
Science

Peak cortisol typically reached. Normal response ≥18-20 mcg/dL confirms adequate adrenal reserve. Cosyntropin has cleared plasma by this point (t½ ~15 min).

Community

N/A: the test is over. Results interpreted by the ordering physician.

1-2 weeks (Acthar Gel)
Science

Infantile spasms: cessation or significant reduction expected within 2 weeks. MS exacerbations: symptom improvement beginning within days to 1 week.

Community

Parents of infants with West syndrome report dramatic spasm reduction in the first 1-2 weeks. MS patients report variable onset: some improve within days, others take the full course.

2-4 weeks (Acthar Gel)
Science

Full treatment effect realized. Begin mandatory taper to prevent adrenal crisis and rebound.

Community

Cushingoid features appear in most patients by this point (moon face, weight gain). Parents and MS patients report the taper phase as challenging: symptoms can fluctuate.

Pharmacokinetics

Half-Life
15min
Bioavailability
~100% (IV); high bioavailability via IM route
Tmax
Immediate (IV); 15-30 minutes (IM)
Data Confidence
high

Source: FDA label and clinical pharmacology references; cosyntropin plasma half-life ~15 minutes

Pharmacokinetics: Active Dose Over Time

t½ = ~15 minutes

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
24
Sequence
SYSMEHFRWGKPVGKKRRPVKVYP
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 9002-60-2 (native ACTH); 16960-16-0 (cosyntropin/tetracosactide)PubChem 16129617 (opens in a new tab)

Who Should Consider ACTH (Cosyntropin/Cortrosyn)

  • Patients undergoing evaluation for adrenal insufficiency
  • Infants with infantile spasms (West syndrome)
  • Multiple sclerosis patients experiencing acute exacerbations
  • Nephrotic syndrome patients refractory to conventional therapy
  • Rheumatology patients with acute flares of inflammatory conditions

Related Peptides

What Changed for ACTH (Cosyntropin/Cortrosyn)

  1. Safety

    Corrected Oct 18, 2026: pregnancy is a label warning for repository corticotropin, not a contraindication; Acthar Gel may cause fetal harm, per the label.

    Before: Pregnancy is contraindicated for therapeutic corticotropin. Animal studies showed embryocidal effects. After: Pregnancy is not on either repository corticotropin label's contraindication list; Acthar Gel may cause fetal harm (section 8.1), so use it only if the benefit justifies the risk

    What this does not mean: Pregnancy still carries the warning (section 8.1). The page had said pregnancy is contraindicated for therapeutic corticotropin; neither the Acthar Gel nor the Cortrophin Gel contraindication list names it.

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

  2. Safety

    Corrected Oct 18, 2026: pregnancy is a label warning for Acthar Gel, not a contraindication, per the label, sections 4 and 8.1.

    Before: Pregnancy: corticotropin has embryocidal effects in animal studies; use only if potential benefit justifies risk After: Pregnancy: not a label contraindication, but the Acthar Gel label says it may cause fetal harm (section 8.1); use only if potential benefit justifies risk

    What this does not mean: Acthar Gel may cause fetal harm, so pregnancy stays on the list as a warning. The page had cited embryocidal effects in animals; the label says its developmental effects were not adequately assessed in animals.

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

  3. Safety

    Corrected Oct 17, 2026: ACTH now carries the Acthar Gel section 4 contraindications, including intravenous use, live vaccines and peptic ulcer, per the label.

    Before: Peptic ulcer and osteoporosis as cautions; no intravenous, infants under 2, live vaccine, ocular herpes simplex, recent surgery, adrenocortical hyperfunction or porcine protein item After: The label section 4 list: intravenous use, infants under 2 with suspected congenital infections, live vaccines, scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction and porcine protein sensitivity

    What this does not mean: Doses and indications did not change. Cortrophin Gel lists all but the infant and live-vaccine lines. The page had called peptic ulcer and osteoporosis cautions and omitted intravenous use, live vaccines and recent surgery.

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

  4. Safety

    FDA made a past hypersensitivity reaction to corticotropin a contraindication for Acthar Gel on Oct 5, 2026, citing anaphylaxis and angioedema, per the label.

    Before: No corticotropin hypersensitivity line; the only hypersensitivity item named cosyntropin. After: Prior hypersensitivity to corticotropin or any inactive ingredient: contraindicated on the Acthar Gel and Purified Cortrophin Gel labels since October 2026; reactions have included anaphylaxis and angioedema

    What this does not mean: Doses and indications did not change. It is one FDA-required change for ACTH products: Purified Cortrophin Gel gained the same contraindication the same day. No cosyntropin (Cortrosyn) label changed.

    Source: Acthar Gel (repository corticotropin injection) prescribing information, NDA 008372 supplement 088, revised 10/2026 (Drugs@FDA label; Recent Major Changes: Contraindications (4) and Warnings and Precautions (5.10), 10/2026) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 8, 20265 Citations

References

  1. [1]Acthar Gel Treatment for Patients with Autoimmune and Inflammatory Diseases (opens in a new tab)PubMed (opens in a new tab)Review

Related Tools

Storage & Stability

Before Reconstitution
Store at 15-30°C (59-86°F). Protect from light. Stable for shelf life indicated on packaging.
After Reconstitution
Use immediately after reconstitution per manufacturer labeling. If not used immediately, discard unused portion.
Temperature
15-30°C (room temperature) for lyophilized powder; 2-8°C for solution formulations

Frequently Asked Questions

No. It's a prescription diagnostic agent requiring a baseline cortisol draw, IV/IM injection, and post-injection cortisol measurements at 30 and 60 minutes. Self-administering without bloodwork is clinically meaningless and dangerous if anaphylaxis occurs.

Cosyntropin is a synthetic 24-amino-acid analog used only for diagnostic testing. Acthar Gel is a repository corticotropin injection from natural porcine pituitary extract containing the full 39-amino-acid ACTH plus other melanocortin peptides. Different manufacturers, different NDAs, different indications, and different mechanisms.

Yes. ACTH is explicitly listed on the WADA Prohibited List under S2.2.2 (Corticotrophins and Their Releasing Factors), banned in- and out-of-competition. This covers cosyntropin, tetracosactide, and repository corticotropin. Documented doping cases exist in professional cycling.

A normal response requires peak serum cortisol ≥18–20 mcg/dL at 30 or 60 minutes post-injection. Failing to reach this threshold indicates adrenocortical insufficiency. The test cannot distinguish primary from secondary AI, you need a plasma ACTH level for that.

Because cosyntropin has exactly one FDA-approved diagnostic dose: 0.25 mg for adults and children ≥2 years. There is no dose escalation and no beginner/moderate/aggressive framing applicable to this compound. The tri-tier structure is a presentation artifact.